Oculis Holding AG OCS
Set alert
At close · Oct 30
After hours · Oct 30, 4:06 PM ET
- YTD
- -58.64%
- 1 year
- -58.89%
- Open
- 8.19
- Prev close
- 8.24
- Mkt cap
- 508.72M
- Vol
- 309.70K
- Avg vol
- 257.45K
- EPS
- -1.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.19
- High
- 8.84
- Forward P/E
- -6.94
- Beta
- 0.20
- Short ratio
- 1.06
- Inst. own
- 37.91%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.67
- 200-d avg
- 23.22
- 1y target
- 51.82
5D chart
Signals (95)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:25 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 5 days ago |
| RSI: Oversold | Oct 27, 2:00 PM | 5 days ago |
| RSI: Oversold | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
News
3 days ago globenewswire.com
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
ZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet…
3 days ago globenewswire.com
Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Positive Phase 2 ACUITY trial findings support Privosegtor's potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
-
1 week ago benzinga.com
Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective,…
1 week ago globenewswire.com
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
-
1 week ago globenewswire.com
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
1 week ago globenewswire.com
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
1 week ago globenewswire.com
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG…
-
1 week ago benzinga.com
Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trialsPrecision Medicine Approach…
1 week ago globenewswire.com
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
1 week ago globenewswire.com
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa…
3 weeks ago defenseworld.net
Oculis (NASDAQ:OCS) Hits New 1-Year Low – Should You Sell?
Oculis Holding AG (NASDAQ: OCS - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $8.30 and last traded at $8.34, with a volume of…
3 weeks ago globenewswire.com
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end
1 month ago globenewswire.com
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life
1 month ago globenewswire.com
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research…
1 month ago globenewswire.com
Oculis Announces Resignation of Lionel Carnot from Board of Directors
Oculis Announces Resignation of Lionel Carnot from Board of Directors ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis" or the "Company"), a global…
1 month ago globenewswire.com
Oculis Announces Resignation of Lionel Carnot from Board of Directors
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address…
1 month ago zacks.com
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in…
1 month ago globenewswire.com
UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026
HANGZHOU, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- UTStarcom Holdings Corp. (“UT” “UTStarcom” or the “Company”) (NASDAQ: UTSI), a global networking solutions provider, made its inaugural appearance…
1 month ago defenseworld.net
Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $39.44
Oculis Holding AG (NASDAQ: OCS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are currently covering the company, Marketbeat Ratings…
1 month ago benzinga.com
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $26 to $39.
1 month ago globenewswire.com
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company's Board of Directors.
2 months ago zacks.com
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
2 months ago globenewswire.com
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
-
2 months ago benzinga.com
Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at…
-
2 months ago benzinga.com
Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.48) by 58.33 percent. This is a 64.91 percent increase over losses of…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Oculis Holding, Maintains $26 Price Target
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and maintains $26 price target.
-
3 months ago benzinga.com
Oculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data
The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need The FDA…
3 months ago benzinga.com
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings beat estimates. Other stocks also falling in pre-market.
-
4 months ago benzinga.com
Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DEDThis FDA-aligned trial…
-
5 months ago benzinga.com
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $42 to $23.
-
5 months ago benzinga.com
Baird Maintains Outperform on Oculis Holding, Lowers Price Target to $38
Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the price target from $49 to $38.
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Stifel Maintains Buy on Oculis Holding, Lowers Price Target to $40
Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $50 to $40.
5 months ago benzinga.com
Why Is Oculis Stock Sinking Monday?
Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to meet the primary endpoint.
-
5 months ago benzinga.com
Guggenheim Maintains Buy on Oculis Holding, Lowers Price Target to $45
Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $75 to $45.
5 months ago benzinga.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
5 months ago benzinga.com
Needham Maintains Buy on Oculis Holding, Lowers Price Target to $38
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $46 to $38.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Oculis Holding, Lowers Price Target to $26
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the price target from $47 to $26.
5 months ago benzinga.com
Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announced to acquire the homebuilder.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
Oculis Holding Reports Topline Results From Phase 3 DIAMOND-1 And DIAMOND-2 Trials Of OCS-01 Eye Drops In Patients With DME; Primary BCVA Endpoint Not Met
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial…
-
5 months ago benzinga.com
Guggenheim Initiates Coverage On Oculis Holding with Buy Rating, Announces Price Target of $75
Guggenheim analyst Yatin Suneja initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rating and announces Price Target of $75.
-
5 months ago benzinga.com
JP Morgan Maintains Overweight on Oculis Holding, Raises Price Target to $42
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and raises the price target from $38 to $42.
-
5 months ago benzinga.com
Needham Maintains Buy on Oculis Holding, Raises Price Target to $46
Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $40 to $46.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $47
HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $44 to $47.
-
5 months ago benzinga.com
Oculis Holding Q1 EPS $(0.63) Misses $(0.49) Estimate, Sales $266.845K Miss $320.000K Estimate
Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.49) by 26.53 percent. This is a 19.48 percent increase over losses of…